These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 29285874)
21. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Dasgupta S; Navarrete AM; Bayry J; Delignat S; Wootla B; André S; Christophe O; Nascimbeni M; Jacquemin M; Martinez-Pomares L; Geijtenbeek TB; Moris A; Saint-Remy JM; Kazatchkine MD; Kaveri SV; Lacroix-Desmazes S Proc Natl Acad Sci U S A; 2007 May; 104(21):8965-70. PubMed ID: 17502612 [TBL] [Abstract][Full Text] [Related]
23. Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A. Peyron I; Dimitrov JD; Delignat S; Gangadharan B; Srivastava A; Kaveri SV; Lacroix-Desmazes S Cell Immunol; 2018 Mar; 325():64-68. PubMed ID: 29395036 [TBL] [Abstract][Full Text] [Related]
24. Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A. Madoiwa S; Yamauchi T; Hakamata Y; Kobayashi E; Arai M; Sugo T; Mimuro J; Sakata Y J Thromb Haemost; 2004 May; 2(5):754-62. PubMed ID: 15099282 [TBL] [Abstract][Full Text] [Related]
25. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin. Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM Front Immunol; 2020; 11():1293. PubMed ID: 32670285 [TBL] [Abstract][Full Text] [Related]
26. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice. Wroblewska A; van Haren SD; Herczenik E; Kaijen P; Ruminska A; Jin SY; Zheng XL; van den Biggelaar M; ten Brinke A; Meijer AB; Voorberg J Blood; 2012 May; 119(22):5294-300. PubMed ID: 22498747 [TBL] [Abstract][Full Text] [Related]
27. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon. Liu L; Mah C; Fletcher BS Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640 [TBL] [Abstract][Full Text] [Related]
28. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. Shi Q; Wilcox DA; Fahs SA; Weiler H; Wells CW; Cooley BC; Desai D; Morateck PA; Gorski J; Montgomery RR J Clin Invest; 2006 Jul; 116(7):1974-82. PubMed ID: 16823491 [TBL] [Abstract][Full Text] [Related]
29. Elimination of factor VIII-specific B cells by immunotoxins composed of a single factor VIII domain fused to Pseudomonas exotoxin A. Brettschneider K; Schmidt A; Kahle J; Orlowski A; Stichel D; Schwabe D; Königs C J Thromb Haemost; 2018 Nov; 16(11):2223-2232. PubMed ID: 30152083 [TBL] [Abstract][Full Text] [Related]
30. Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII. Liu CL; Ye P; Lin J; Djukovic D; Miao CH J Thromb Haemost; 2014 Jun; 12(6):921-31. PubMed ID: 24684505 [TBL] [Abstract][Full Text] [Related]
31. A cellular viewpoint of anti-FVIII immune response in hemophilia A. André S; Meslier Y; Dimitrov JD; Repessé Y; Kaveri SV; Lacroix-Desmazes S; Dasgupta S Clin Rev Allergy Immunol; 2009 Oct; 37(2):105-13. PubMed ID: 19165635 [TBL] [Abstract][Full Text] [Related]
32. Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation. Zerra PE; Arthur CM; Chonat S; Maier CL; Mener A; Shin S; Allen JWL; Baldwin WH; Cox C; Verkerke H; Jajosky RP; Tormey CA; Meeks SL; Stowell SR Front Immunol; 2020; 11():905. PubMed ID: 32582142 [TBL] [Abstract][Full Text] [Related]
33. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors. Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236 [TBL] [Abstract][Full Text] [Related]
34. Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response. Waters B; Qadura M; Burnett E; Chegeni R; Labelle A; Thompson P; Hough C; Lillicrap D Blood; 2009 Jan; 113(1):193-203. PubMed ID: 18815284 [TBL] [Abstract][Full Text] [Related]
35. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice. Merlin S; Cannizzo ES; Borroni E; Bruscaggin V; Schinco P; Tulalamba W; Chuah MK; Arruda VR; VandenDriessche T; Prat M; Valente G; Follenzi A Mol Ther; 2017 Aug; 25(8):1815-1830. PubMed ID: 28552407 [TBL] [Abstract][Full Text] [Related]
36. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Hausl C; Ahmad RU; Sasgary M; Doering CB; Lollar P; Richter G; Schwarz HP; Turecek PL; Reipert BM Blood; 2005 Nov; 106(10):3415-22. PubMed ID: 16091456 [TBL] [Abstract][Full Text] [Related]
37. Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro. Werwitzke S; Vollack N; von Hornung M; Kalippke K; Kutzschbach J; Trummer A; Ganser A; Tiede A Thromb Haemost; 2015 Nov; 114(6):1127-35. PubMed ID: 26245154 [TBL] [Abstract][Full Text] [Related]
38. B cell-activating factor modulates the factor VIII immune response in hemophilia A. Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651716 [TBL] [Abstract][Full Text] [Related]
39. Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII. Sasgary M; Ahmad RU; Schwarz HP; Turecek PL; Reipert BM Thromb Haemost; 2002 Feb; 87(2):266-72. PubMed ID: 11858486 [TBL] [Abstract][Full Text] [Related]
40. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity. Doering CB; Gangadharan B; Dukart HZ; Spencer HT Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]